Genome Engineering, CRISPR-Tech
piIndication.tooltipPi0
-3.50% 0.65%Last Trading Day
Last 12M
Risk
Genome Engineering
United Kingdom
The CRISPR CopyPortfolio was created to initiate exposure to the companies investing in the innovative gene editing tool, CRISPR, which is revolutionising biotechnology. The investment strategy contains large-cap companies with a cumulative market cap of $300 billion, so investors get top-of-the-line companies in their portfolio. In addition, the CopyPortfolio contains small-cap biotech companies (with a market cap of $1 billion or lower), each with the potential to positively impact the future of the life sciences. The CRISPR CopyPortfolio allocates equal weight to each stock within its composition, to create a managed, balanced portfolio that gives investors one-click exposure to one of the most innovative fields in biotech today. CopyPortfolio™ is a portfolio management product by eToro. This investment strategy was created and is managed by eToro’s Investment Committee. The minimum investment is $5,000. ... Show More
0.00 -
This Year’s Performance. Risk Score Considers Last 7D.
Genome Engineering
Pinned Post
Genome Engineering @CRISPR-Tech
Turn on notifications
Flag as spam
Dear Investors, Here is your monthly update for September 2018 The CRISPR-Tech is a thematic investment portfolio, which means its strategy is based on a particular investment theme, in this case selecting bio-tech or pharmateutical stocks focusing on CRISPR-Technology, still at a relative early stage in terms of widespread adoption. This portfolio is built and managed by eToro’s investment committee. The S&P500 is currently up 11% this year. This CopyPortfolio is currently up 7.5%, below that of the S&P500. This month was a weak performing month for the portfolio closing at a loss of 2.2%. Losses have continued into October. Some studies have indicarted certain gene-editing techniques may have side-effects, as such CRISPR gene editing tools are still at an early stage in providing a clear treatment for terminal illnesses. This CopyPortfolio is a long-term investment vehicle. Therefore, since market trends can change over time, you should set realistic goals and assess your investment performance over a prolonged period. The risk remained the same for this CopyPortfolio over last month. As this is as a relatively emerging market and some of the stocks have a smaller market cap compared to others, increaed volatility in this portfolio is possible. Increased risk, can mean larger swings both ways in terms of profit and loss. Please bear this in mind. Similar to blokchain the stocks in this portfolio are competing to be the market leader in a new emerging industry. This portfolio provides investors diversification among this sector and protects them from losses if one specific stock they preferred was to suffer losses. If you are planning to add funds to your existing investment, you can do so by closing your current investment and reopen it with your desired investment amount. In regards to new CopyPortfilios, eToro will soon be launching <a href="/people/driverless" class="e-link">@Driverless</a>, an investment strategy based on the self-driving car sector. Please look out for further correspondence in regards to this. Please remember past performance is not indicative of any future performance. <a href="/markets/ntla" class="e-link">$NTLA (Intellia Therapeutics Inc)</a>, <a href="/markets/mrk" class="e-link">$MRK (Merck)</a>, <a href="/markets/clls" class="e-link">$CLLS (Cellectis SA)</a>, <a href="/markets/edit" class="e-link">$EDIT (Editas Medicine Inc)</a>, <a href="/markets/a" class="e-link">$A (Agilent Technologies Inc)</a>, <a href="/markets/sgmo" class="e-link">$SGMO (Sangamo Biosciences Inc)</a>, <a href="/markets/regn" class="e-link">$REGN (Regeneron Pharmaceuticals)</a> ... Show More
User Feed
Genome Engineering @CRISPR-Tech
Turn on notifications
Flag as spam
Dear Investors, Here is your monthly update for August 2018 The CRISPR-Tech CopyFund is a thematic investment portfolio, which means its strategy is based on a particular investment theme, in this case selecting bio-tech or pharmateutical stocks focusing on CRISPR-Technology. This CopyFund’s portfolio is built by eToro’s investment committee. The S&P500 is currently up 10% this year. This CopyFund’s portfolio is currently up 15%, outperforming the index by 50%. This month was a strong month for the CopyFund closing at a significant profit of 11%. This CopyFund is a long-term investment vehicle. Therefore, since market trends can change over time, you should set realistic goals and assess your investment performance over a prolonged period. The risk remained the same for this CopyFund over last month. As published last month you can read about CRISPR technology and its growth potential here: <a href="https://etoro.tw/2LU4F6E" class="e-link" target="_blank" rel="noopener noreferrer">etoro.tw/2LU4F6E</a> As this is as a relatively emerging market and some of the stocks have a smaller market cap compared to others, increaed volatility in this portfolio is possible. Increased risk, can mean larger swings both ways in terms of profit and loss. Please bear this in mind. Similar to blokchain the stocks in this portfolio are competing to be the market leader in a new emerging industry. This portfolio provides investors diversification among this sector and protects them from losses if one specific stock they preferred was to suffer losses. If you are planning to add funds to your existing investment, you can do so by closing your current investment and reopen it with your desired investment amount. Some clients have already added the <a href="/people/cannabiscare" class="e-link">@CannabisCare</a> investment strategy to their watchlist, another bio-tech portfolio. Further communications around the opening of this portfolio will be made in due course. Please remember past performance is not indicative of any future performance. <a href="/markets/ntla" class="e-link">$NTLA (Intellia Therapeutics Inc)</a>, <a href="/markets/mrk" class="e-link">$MRK (Merck)</a>, <a href="/markets/clls" class="e-link">$CLLS (Cellectis SA)</a>, <a href="/markets/edit" class="e-link">$EDIT (Editas Medicine Inc)</a>, <a href="/markets/a" class="e-link">$A (Agilent Technologies Inc)</a>, <a href="/markets/sgmo" class="e-link">$SGMO (Sangamo Biosciences Inc)</a>, <a href="/markets/regn" class="e-link">$REGN (Regeneron Pharmaceuticals)</a> ... Show More
Genome Engineering @CRISPR-Tech
Turn on notifications
Flag as spam
Dear Investors, Here is your monthly update for July 2018 The CRISPR-Tech CopyFund is a thematic investment portfolio, which means its strategy is based on a particular investment theme, in this case selecting bio-tech or pharmateutical stocks focusing on CRISPR-Technology. This CopyFund’s portfolio is built by eToro’s investment committee. The <a href="/markets/spx500" class="e-link">$SPX500</a> is currently up 6.5% this year. This CopyFund’s portfolio is currently up 2.3%, no longer outperforming the index. This month was a flat month for the CopyFund closing in a loss of 0.5%. This CopyFund is a long-term investment vehicle. Therefore, since market trends can change over time, you should set realistic goals and assess your investment performance over a prolonged period. The risk remained the same for this CopyFund over the last month. You can read about CRISPR technology and its growth potential here: <a href="https://etoro.tw/2LU4F6E" class="e-link" target="_blank" rel="noopener noreferrer">etoro.tw/2LU4F6E</a> As this is as a relatively emerging market and some of the stocks have a smaller market cap compared to others, increaed volatility in this portfolio is possible. Increased risk, can mean larger swings both ways in terms of profit and loss. Please bear this in mind. If you are planning to add funds to your existing investment, you can do so by closing your current investment and reopen it with your desired investment amount. Please remember past performance is not indicative of any future performance. <a href="/markets/ntla" class="e-link">$NTLA (Intellia Therapeutics Inc)</a>, <a href="/markets/mrk" class="e-link">$MRK (Merck)</a>, <a href="/markets/clls" class="e-link">$CLLS (Cellectis SA)</a>, <a href="/markets/edit" class="e-link">$EDIT (Editas Medicine Inc)</a>, <a href="/markets/a" class="e-link">$A (Agilent Technologies Inc)</a>, <a href="/markets/sgmo" class="e-link">$SGMO (Sangamo Biosciences Inc)</a>, <a href="/markets/regn" class="e-link">$REGN (Regeneron Pharmaceuticals)</a> " ... Show More
Genome Engineering @CRISPR-Tech
Turn on notifications
Flag as spam
"Dear Investors, Here is your monthly update for June 2018 The CRISPR-Tech CopyFund is a thematic investment portfolio, which means its strategy is based on a particular investment theme, in this case selecting bio-tech or pharmateutical stocks focusing on CRISPR-Technology. This CopyFund’s portfolio is built by eToro’s investment committee. The S&P500 is currently up 2.6% this year. This CopyFund’s portfolio is currently up 4%, outperforming the index by almost 100%. This month was an average performing month for the CopyFund in terms of profit, closing in a slight drawdown. This CopyFund is a long-term investment vehicle. Therefore, since market trends can change over time, you should set realistic goals and assess your investment performance over a prolonged period. The risk decreased for this CopyFund over last month. There were no quarterly earnings reports released this past month, which may lead to market volatility. As this is as a relatively emerging market and some of the stocks have a smaller market cap compared to others, increaed volatility in this portfolio is possible. Increased risk, can mean larger swings both ways in terms of profit and loss. Please bear this in mind. If you are planning to add funds to your existing investment, you can do so by closing your current investment and reopen it with your desired investment amount. We shall soon be opening some new CopyFunds for investment, feel free to to add the <a href="/people/sharptraders" class="e-link">@SharpTraders</a> CopyFund to your watchlist, if you are interested in further diversifying your portfolio. Please remember past performance is not indicative of any future performance. <a href="/markets/ntla" class="e-link">$NTLA (Intellia Therapeutics Inc)</a>, <a href="/markets/mrk" class="e-link">$MRK (Merck)</a>, <a href="/markets/clls" class="e-link">$CLLS (Cellectis SA)</a>, <a href="/markets/edit" class="e-link">$EDIT (Editas Medicine Inc)</a>, <a href="/markets/a" class="e-link">$A (Agilent Technologies Inc)</a>, <a href="/markets/sgmo" class="e-link">$SGMO (Sangamo Biosciences Inc)</a>, <a href="/markets/regn" class="e-link">$REGN (Regeneron Pharmaceuticals)</a> " ... Show More
Genome Engineering @CRISPR-Tech
Turn on notifications
Flag as spam
"Dear Investors, Here is your monthly update for May 2018 The CRISPR-Tech CopyFund is a thematic investment portfolio, which means its strategy is based on a particular investment theme, in this case selecting bio-tech or pharmateutical stocks focusing on CRISPR-Technology. This CopyFund’s portfolio is built by eToro’s investment committee. The S&P500 is currently up 2% this year. This CopyFund’s portfolio is currently up 4%, outperformingthe index by 100%. This month was a top performing month for the CopyFund in terms of profit, closing 8% higher for the month. This CopyFund is a long-term investment vehicle. Therefore, since market trends can change over time, you should set realistic goals and assess your investment performance over a prolonged period. The risk increased for this CopyFund over last month was due to quarterly earnings reports among the selected stocks in the portfolio and general volatility among the technology sector in the US. Increased risk, can mean larger swings both ways in terms of profit and loss. Please bear this in mind. If you are planning to add funds to your existing investment, you can do so by closing your current investment and reopen it with your desired investment amount. The rebalancing for this CopyFund takes place upon the discretion of the investment committee and any communications about this will be made in advance. Please remember past performance is not indicative of any future performance. <a href="/markets/ntla" class="e-link">$NTLA (Intellia Therapeutics Inc)</a>, <a href="/markets/mrk" class="e-link">$MRK (Merck)</a>, <a href="/markets/clls" class="e-link">$CLLS (Cellectis SA)</a>, <a href="/markets/edit" class="e-link">$EDIT (Editas Medicine Inc)</a>, <a href="/markets/a" class="e-link">$A (Agilent Technologies Inc)</a>, <a href="/markets/sgmo" class="e-link">$SGMO (Sangamo Biosciences Inc)</a>, $REGN" ... Show More